Join us at the Digiday Publishing Summit from March 24-26 in Vail
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Brands bet on sustained enthusiasm for women’s basketball ahead of March Madness
For some marketers, the spring tournament is second only to the Super Bowl in audience size and appeal.
Advertisers put SSPs and curators under the microscope in sell-side push for ad tech fee transparency
They want proof that ad tech vendors are taking only what they claim because the more money that reaches publishers, the better their chances of winning the impressions they actually want.
Digiday+ Research: YouTube usage drops as fewer brands put a large amount of marketing spend toward the platform
Brands’ usage of YouTube has dropped off, while more brands are spending just a little on YouTube marketing and fewer are spending a lot.